These findings suggest that COX-2 and PPAR-γ are critical for the anti-cancer effects of CBD in lung cancer and provide strong evidence that the molecular targets of CBD may at least be, in part, dependent on the cancer cell type being treated. This evidence concerns the gene PTGS2 and lung carcinoma.